Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
It has been reported that the 9-aminoanthracycline amrubicin shows good efficacy in human tumor xenograft models. We studied the disposition and metabolism of amrubicin in mice, in comparison with those of doxorubicin. Amrubicinol, a 13-hydroxy metabolite of amrubicin, which is 10 to 100 times more cytotoxic than amrubicin, was detected as a major metabolite in blood and tissues, and aglycones of amrubicin were also detected. A pharmacokinetic study revealed that amrubicin had a smaller distribution volume and a shorter half-life than doxorubicin. In several normal tissues, the levels of amrubicin and amrubicinol were lower than those of doxorubicin. In contrast, the tumor levels of amrubicinol in the mice treated with amrubicin were higher than those of doxorubicin in the mice treated with that drug, in tumors that are sensitive to amrubicin. These results suggest that the potent therapeutic activity of amrubicin is caused by the selective distribution of its highly active metabolite, amrubicinol, in tumors.
Noguchi
T
T
Research Center, Sumitomo Pharmaceuticals Co., Ltd., Osaka.
Ichii
S
S
Morisada
S
S
Yamaoka
T
T
Yanagi
Y
Y
D000818:Animals; D018943:Anthracyclines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D004317:Doxorubicin / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008954:Models, Biological; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C116173:amrubicinol; D004317:Doxorubicin; C055866:amrubicin